Vor Biopharma (VOR) Total Liabilities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Total Liabilities data on file, last reported at $657.2 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $657.2 million, up 1419.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $657.2 million (up 1419.71% YoY), and the FY2025 annual result was $628.4 million, up 1259.46% from the prior year.
• Total Liabilities climbed to $657.2 million in Q1 2026 per VOR's latest filing, from $628.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $2.4 billion in Q3 2025 and troughed at $39.8 million in Q1 2022.
• A 5-year average of $352.6 million and a median of $47.4 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities decreased 10.79% in 2024, then surged 5480.73% in 2025.
• A 5-year view of Total Liabilities shows it stood at $48.8 million in 2022, then declined by 2.78% to $47.4 million in 2023, then declined by 2.48% to $46.2 million in 2024, then surged by 1259.46% to $628.4 million in 2025, then gained by 4.57% to $657.2 million in 2026.
• Business Quant data shows VOR's Total Liabilities at $657.2 million in Q1 2026, $628.4 million in Q4 2025, and $2.4 billion in Q3 2025.